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Pancreatic cancer is an aggressive cancer with poor
prognosis. Despite its low incidence, it is the 4th cause of
cancer-related death in the US. Treatment options have
only marginally improved on survival rates, which have
remained low, with about 25% survival at 12 months and
5% at 5 years. For these reasons, new therapeutic strategies
are urgently needed including immunotherapeutic
approaches. We have investigated the immunotherapeutic
effect of IMM-101, a heat-killed whole cell preparation of
Mycobacterium obuense currently undergoing investiga-
tion in a Phase II clinical trial in pancreatic cancer
(EudraCT n. 2010-022757-42), in two clinically relevant
murine models of pancreatic cancer, which histologically
mirror human pancreatic adenocarcinomas. Genetically-
modified mice bearing mutations in Kras, p53 and
Pdx-Cre (KPC mice) were treated with IMM-101 immedi-
ately after development of a palpable tumour. Whereas
IMM-101 treatment was unable to effect survival in this
rather aggressive model, it did, however, significant
decrease metastatic burden. Moreover, it appeared to
expand a population of antigen experienced CD8+ T cells
bearing CD45RBlowCD44high and able to produce IFN-g
and perforin. On the basis of these promising obser-
vations, we explored further whether treatment with
IMM-101 could induce cytotoxic CD8+ T cells able to
effect disease outcome. We treated mice bearing muta-
tions in Kras and Pdx-Cre (KC mice) with IMM-101 and
found that not only was survival significantly increased,
but also that IMM-101 treatment altered their immune
response to disease. We observed systemic T cell activa-
tion at the tumour site, the draining lymph nodes and the
spleen, as measured by CD69 expression on T cells. More
importantly, in mice treated with IMM-101, CD8+ T cells
were found in higher numbers compared to untreated
mice, in both the draining lymph nodes and at the tumour
site. These CD8+ T cells were characterized by increased
production of IFN-g, perforin and granzyme, identifying
them as cytotoxic CD8+ effector T cells. To further
confirm that the mode of action of IMM-101 was directly
depended on CD8+ T cells, we depleted these cells in
treated mice with a neutralizing antibody. We found that
depletion of CD8+ T cells, but not for example depletion
of NK cells, was responsible for the loss of therapeutic
effect. We are currently sequencing the CD8+ T cell TCR
to determine specificity. We propose that treatment with
IMM-101 is able to induce CD8+ T cell-dependent
protective effects in the host and limit disease progression.
We expect that in combination therapies these immu-
notherapeutic effects may be further increased.
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